Eunsung Jun1, Jaeyoon Jung2, Seong-Yun Jeong3, Eun Kyung Choi4, Moon Bo Kim5, Ji Sun Lee5, Seung-Mo Hong6, Hyang Sook Seol2, Changmo Hwang7, Robert M Hoffman8, In Kyong Shim9, Suhwan Chang10, Song Cheol Kim11. 1. Departments of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 2. Division of Biomedical Sciences, Department of Physiology, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 3. Center for Advancing Cancer Therapeutics, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 4. Center for Advancing Cancer Therapeutics, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 5. Metabio, Inc. Gangdong-gu, Seoul, Republic of Korea. 6. Department of Pathology, University of Ulsan College of Medicine, Songpa-gu, Seoul, Republic of Korea. 7. Biomedical Engineering Research Center, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 8. Department of Surgery, University of California, San Diego, CA, U.S.A. AntiCancer, Inc., San Diego, CA, U.S.A. 9. Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea. 10. Division of Biomedical Sciences, Department of Physiology, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea drksc@amc.seoul.kr suhwan.chang@amc.seoul.kr. 11. Departments of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Songpa-gu, Seoul, Republic of Korea drksc@amc.seoul.kr suhwan.chang@amc.seoul.kr.
Abstract
BACKGROUND: To effectively use pancreatic cancer patient-derived xenograft (PDX) models in translational research, successful PDX engraftment of surgical specimens in immune-deficient mice is needed. MATERIALS AND METHODS: A total of 102 patients underwent pancreatic cancer resection using various procedures. Tumor tissue from all patents was implanted subcutaneously into mice. Tumor engraftment and growth in mice were determined. Engraftment was tested for correlation with operation type, time, tumor size, and oncogene expression using immunohistoculture. RESULTS: Multivariate analysis showed that a tumor size of more than 3.5 cm in the patient was a significant factor related to successful PDX engraftment. In contrast, there was no correlation of engraftment with surgical procedure, time needed to remove the specimen, tumor differentiation, lymph node metastasis, and protein expression of p53, Receptor tyrosine-protein kinase erbB-2 (CERBB2), or deleted in pancreatic carcinoma locus 4 (DPC4). CONCLUSION: A minimum tumor size in the patient is an important factor for successful tumor engraftment. Copyright
BACKGROUND: To effectively use pancreatic cancerpatient-derived xenograft (PDX) models in translational research, successful PDX engraftment of surgical specimens in immune-deficient mice is needed. MATERIALS AND METHODS: A total of 102 patients underwent pancreatic cancer resection using various procedures. Tumor tissue from all patents was implanted subcutaneously into mice. Tumor engraftment and growth in mice were determined. Engraftment was tested for correlation with operation type, time, tumor size, and oncogene expression using immunohistoculture. RESULTS: Multivariate analysis showed that a tumor size of more than 3.5 cm in the patient was a significant factor related to successful PDX engraftment. In contrast, there was no correlation of engraftment with surgical procedure, time needed to remove the specimen, tumor differentiation, lymph node metastasis, and protein expression of p53, Receptor tyrosine-protein kinase erbB-2 (CERBB2), or deleted in pancreatic carcinoma locus 4 (DPC4). CONCLUSION: A minimum tumor size in the patient is an important factor for successful tumor engraftment. Copyright
Authors: Dimitrios E Magouliotis; Kostas Lafazanis; Fani Koutsougianni; Nikos Sakellaridis; Maria Ioannou; Dimitris Zacharoulis; Konstantinos Dimas Journal: In Vivo Date: 2022 May-Jun Impact factor: 2.406
Authors: Zhenyang Liu; Michael Ho-Young Ahn; Tomohiro Kurokawa; Amy Ly; Gong Zhang; Fuyou Wang; Teppei Yamada; Ananthan Sadagopan; Jane Cheng; Cristina R Ferrone; Andrew S Liss; Kim C Honselmann; Gregory R Wojtkiewicz; Soldano Ferrone; Xinhui Wang Journal: J Transl Med Date: 2020-06-24 Impact factor: 5.531
Authors: Karl Roland Ehrenberg; Jianpeng Gao; Felix Oppel; Stephanie Frank; Na Kang; Sebastian M Dieter; Friederike Herbst; Lino Möhrmann; Taronish D Dubash; Erik R Schulz; Hendrik Strakerjahn; Klara M Giessler; Sarah Weber; Ava Oberlack; Eva-Maria Rief; Oliver Strobel; Frank Bergmann; Felix Lasitschka; Jürgen Weitz; Hanno Glimm; Claudia R Ball Journal: Cells Date: 2019-02-10 Impact factor: 6.600
Authors: Sun Il Choi; A-Ra Jeon; Min Kyeong Kim; Yu-Sun Lee; Ji Eun Im; Jung-Wook Koh; Sung-Sik Han; Sun-Young Kong; Kyong-Ah Yoon; Young-Hwan Koh; Ju Hee Lee; Woo Jin Lee; Sang-Jae Park; En Kyung Hong; Sang Myung Woo; Yun-Hee Kim Journal: Front Oncol Date: 2019-09-13 Impact factor: 6.244
Authors: Ilaria Pergolini; Vicente Morales-Oyarvide; Mari Mino-Kenudson; Kim C Honselmann; Matthew W Rosenbaum; Sabikun Nahar; Marina Kem; Cristina R Ferrone; Keith D Lillemoe; Nabeel Bardeesy; David P Ryan; Sarah P Thayer; Andrew L Warshaw; Carlos Fernández-Del Castillo; Andrew S Liss Journal: PLoS One Date: 2017-08-30 Impact factor: 3.240
Authors: Eunsung Jun; Seung-Mo Hong; Hyun Ju Yoo; Moon-Bo Kim; Ji Sun Won; Soyeon An; In Kyong Shim; Suhwan Chang; Robert M Hoffman; Song Cheol Kim Journal: Oncotarget Date: 2017-12-21